Our study was conducted to further investigate the single-dose approach of @entity99 vaccination, while providing supportive data on the flexibility of booster administration. @entity1 received at least one dose of Avaxim 80U Pediatric at 11-23  months of age, and they will be followed for 10  years. We report here the fourth and fifth years after the first vaccination. Group assignment was based on whether the @entity1 received 1 dose and no booster during the study (Group 1) or 2 doses and no further booster (Group 2). Anti-HAV antibody concentrations were assessed at each annual visit. Of the 546 initial @entity1 , 441 (80.8%) and 412 (75.5%) were followed up 4 and 5  years after vaccination, respectively. Of the 411 subjects evaluable at Year 5, 318 had received one vaccine dose and 85 had received two. Seroprotection rates were still high in Group 1 (99.7%) and in Group 2 (100%) 5  years after one or two doses of Avaxim 80U Pediatric, correspondingly. Anti-HAV geometric mean concentrations decreased in both groups compared to what they were 3  years after vaccination, while remaining well above the 10  mIU/mL threshold 5  years after vaccination. The highest concentrations were found in the @entity1 who received 2 vaccine doses. @entity99 humoral immunity induced by a single dose of inactivated @entity99 vaccine can persist for at least 5  years in a paediatric population. The study results also support recommendations in favour of a flexible time window for booster vaccination.

Five-year follow-up of immune response after one or two doses of inactivated XXXX vaccine given at 1  year of age in the Mendoza Province of Argentina.

@entity1 :: ('9606', 'Species') :: ['participants', 'children', 'Participants'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis A', 'Hepatitis A']
@entity99 :: (MESH:D056486,Disease) :: ['hepatitis A']
